reMYND Commences P-l Study of RES19-T for Alzheimer’s Disease

Shots:

• The P-l trial will evaluate the safety, tolerability, and PK of ReS19-T for the treatment of AD. In preclinical studies, ReS19-T has shown to robustly restore synaptic plasticity with an acute response and improve inflammation and AD pathology over a longer treatment duration
• reMYND has a broad pipeline of novel programs in development, with a diabetes program scheduled to initiate human trials in mid-2021
• RES19-T is a novel approach addressing the AD at its root and restore cognition in patients by reducing the cellular damage associated with memory loss

Click here ­to­ read full press release/ article | Ref: Globe Newswire | Image: reMYND